ISRCTN99672071已完成不适用
Efficacy of rituximab in patients with systemic sclerosis: an open label randomised controlled study
niversity Hospital of Patras (Greece)0 个研究点目标入组 15 人开始时间: 2008年10月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Both males and females
- •2. Detection of anti-Scl-70 autoantibodies in their sera
- •3. Presence of SSc-associated interstitial lung disease (ILD) as indicated by findings in either high-resolution computed tomography (HRCT) of the chest or pulmonary function tests (PFT) or both
- •4. Absence of any changes in medications and/or dosage of treatment administered during the last 12 months before enrolment
排除标准
- •Aged less than 18 years
研究者
相似试验
已完成
2 期
Rituximab in Systemic SclerosisSystemic SclerosisNCT01748084Assistance Publique - Hôpitaux de Paris22
已完成
不适用
Prospective study on the effects of rituximab on synovial tissue of patients with rheumatoid arthritisRheumatoid arthritisISRCTN05568900Academic Medical Centre (AMC) (The Netherlands)32
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300
进行中（未招募）
1 期
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
已完成
不适用
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20